mixed-lymphocyte-reaction-assay-appnote1920x640
Whitepaper

ImmuSignature™ MLR: Rapid high-throughput assessment of therapeutic immunogenicity

Regulatory bodies have provided recommendations for in vitro assays and to leverage high throughput screening technologies to increase the likelihood of rapidly moving therapeutic candidates into clinical trials.

This white paper discusses the requirements of regulatory bodies and how a rapid immunogenicity assessment screening can provide invaluable support for your application.

In this white paper you will learn:

  • What an investigational new drug filing is
  • Why assessing immunogenicity of therapeutic candidates is crucial for IND filing
  • The advantages and limitations of MLR assays for an IND filing

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

ImmuSignature™ MLR: Rapid high-throughput assessment of therapeutic immunogenicity

Download Whitepaper